CN108853016A - A kind of ophthalmic solution sodium eye drops and preparation method thereof - Google Patents
A kind of ophthalmic solution sodium eye drops and preparation method thereof Download PDFInfo
- Publication number
- CN108853016A CN108853016A CN201811118247.8A CN201811118247A CN108853016A CN 108853016 A CN108853016 A CN 108853016A CN 201811118247 A CN201811118247 A CN 201811118247A CN 108853016 A CN108853016 A CN 108853016A
- Authority
- CN
- China
- Prior art keywords
- eye drops
- ophthalmic solution
- solution sodium
- eye
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a kind of ophthalmic solution sodium eye drops and preparation method thereof without classical preservative belongs to pharmaceutical preparations technology field.The present invention, which solves ophthalmic solution sodium eye drops, leads to the side effects such as many adverse reactions of eyes as the long-term administration of xerophthalmia.Eye drops of the present invention is almost nonirritant to eyes, while this product property is stablized.
Description
Technical field
The invention belongs to pharmaceutical preparations technology fields, and in particular to a kind of ophthalmic solution sodium eye drops and preparation method thereof.
Background technique
Ophthalmic solution sodium eye drops is the product (trade name that towering drugmaker and Inspire drugmaker develop jointly：
Diquas®), for treating scheroma, listed in Japan within 2010.It is raw that China has approved towering pharmacy on October 20th, 2017
The ophthalmic solution sodium eye drops of production lists（Trade name：Li Aisi®）. Diquas®It is the first P2Y2 receptor that the whole world is approved listing
Agonist eye drops treats scheroma with novel mechanism：By promoting water and mucin secretion to improve dry eye symptoms, make tear
Film is closer to normal condition.In the clinical research of Japan, serious eye and systemic bad reflection are not found.This product tolerance
Property is good, therefore can be used for long-term treatment dry eye symptoms.
Commercially available Diquas®The additive that the eye drops is recorded in specification is dibastic sodium phosphate hydrate（Buffer）,EDTA-
2Na（Stabilizer）, sodium chloride and potassium chloride（Isotonic agent）And chlorhexidine gluconate（Preservative）.Overstate phosphorus in the ground of Chinese import
Rope sodium eye drops（Trade name：Li Aisi®）The additive recorded in specification is dibastic sodium phosphate hydrate（Buffer）, sodium chloride
With potassium chloride（Isotonic agent）And benzalkonium chloride（Preservative）.
The usage and dosage of specification notebook eye drops is one time 1~2 drop, 6 times a day, in 655 patient tests record,
It was found that adverse reaction（Including clinical examination value exception）155 (23.7%).Main adverse reaction is Eye irritation sense 44
（6.7%）, secretion 31 (4.7%), conjunctival congestion 24 (3.7%), ophthalmodynia 18（2.7%）, scratchiness 16 (2.4%),
Foreign body sensation 14 (2.1%), eye sense of discomfort 7 (1.1%) etc..（When approval）It was found that drug withdrawal etc. should be taken appropriate when adverse reaction
Kind disposition.
Document：The Chinese drug standards, 2014,15（1）:12~15, Ophthalmologe, 2012,9（11）:1064~
1070, Br J Ophthalmol, 2014,98（7）:926~931 report, the bacteriostatic agent in eye-drops preparations has thorn to ocular tissue
Swash property, or even will cause ocular tissue's damage.And the preparations such as eye drops for needing frequent drug administration, bacteriostatic agent can be with administration
The increase of number is built up at ocular tissue, to cause biggish injury to eyes.
Benzalkonium chloride is a kind of most bacteriostatic agent of current application, document Clin Ophthalmol, 2016,10:331~
336 reports, the ophthalmic preparation more than 70% is using benzalkonium chloride as bacteriostatic agent.The bacteriostatic agents such as benzalkonium chloride can destroy tear film, damage
Ocular epithelial cell, this damaging action can aggravate with the extension of administration time, for glaucoma and scheroma etc.
The patient for needing long-term administration may cause " secondary " injury using the eye drops containing bacteriostatic agent to their ocular tissue
（Document：Expert Rev Ophthalmol, 2009,4（1）：59~64）.
Chitosan is a kind of cationic polymer, has biocompatibility and biodegradable property.In its structure
Amino has positive charge, can form hydrogen bond with the negative electrical charge that the sialic acid residues of mucin have or ionic interaction occurs,
Promote corneal osmosis.Further research confirms tight between the combination of chitosan and mucin facilitates opening angle film epithelial cell
Close connection promotes infiltration of the drug to cornea.
In existing technical literature report, the patent document CN108403625 of Dongguan solution stone medicine discloses one kind and contains chela
The ophthalmic solution sodium eye drops of mixture, the technology solved are the precipitation problems in ophthalmic solution sodium eye drops；Towering pharmacy is public
The patent document CN1228053 of department discloses the eye drops containing diuridine phosphoric acid, the technology solved be used it is effective dense
The preservative benzalkonium chloride of degree；The patent document CN103282039 of towering drugmaker discloses the eye drip containing ophthalmic solution
Liquid and preparation method thereof, the technology solved are to inhibit the insoluble precipitate of eye drops using analogs such as chelating agent EDTA-2Na
Generation.
So far, it is not yet reported that not by using the quaternary ammonium salt preservative of toxicity（Such as benzalkonium chloride, gluconic acid
Chlorhexidine）Obtain being able to maintain with the chelating agent such as EDTA-2Na of toxicity control enough Antifungal activities and stability overstate
Phosphorus rope sodium eye drip liquid product.
In view of the foregoing, it is desirable to provide the eye drops that can preferably alleviate dry eye condition, and the eye drops makes
With conveniently, safely, the duration it is longer.Specifically, it is highly desirable to develop that administration number of times is less, Antifungal activity is higher, steady
Qualitative better eye drops, more effectively treats dry eye condition.
Summary of the invention
Technical problem
In view of the above problems, it is an object of the present invention to by ophthalmic solution sodium and without containing preservative benzalkonium chloride or grape
It saccharic acid Chlorhexidine and is provided without containing edetate quasi-chelate compound with saving the one of efficiency and stability enough
Kind ophthalmic solution sodium eye drops.Another object of the present invention is to provide the preparation methods of this ophthalmic solution sodium eye drops.This
A further object for invention is that providing this ophthalmic solution sodium eye drops is preparing the utilization in dry eye drugs.
The means solved the problems, such as
In view of the above problems, the present inventor concentrates on studies to above-mentioned eye drops, prepares and inquires into that a variety of eye drops are common to be added
The ophthalmic solution sodium eye drops for adding agent, as a result it has surprisingly been found that by using shitosan macromolecule compound as part
Thickener double as bacteriostatic agent, by boric acid as pH adjusting agent as fungicide and borax composition buffer to isotonic system, it is non-
Often a kind of new ophthalmic solution sodium eye drops it has been made startlingly, which is capable of providing a kind of irritation, stability
Eye drops more superior than existing eye drops.
Currently, the eye-drops preparations listed both at home and abroad is mostly multiple-unit container, preparation in production, storage, transport, used
Vulnerable to microbial contamination in journey.It therefore, generally need to be in prescription in order to reduce the contamination probability of eye-drops preparations to the maximum extent
Bacteriostatic agent is added, prevents the pollution of microorganism in use process.Bacteriostatic agent must assure that enough within the validity period of eye-drops preparations
Effect.Meanwhile to reduce its pollution in use, Britain and European Pharmacopoeia（BP and EP）Provide that eye-drops preparations is opened
It's 4 weeks must not past the pot life afterwards.
Bacteriostatic agent is generally divided into following a few classes according to chemical structure and property：Quaternary ammonium salts, such as benzalkonium chloride, benzalkonium bromide
Equal cationic surfactants；Organic mercury class, such as thimerosal, phenylmercuric acetate；Alcohols, such as anesin, benzyl alcohol；It is right
Hydroxybenzoic acid esters, ethyl hydroxy benzoate, methyl hydroxybenzoate etc.；Acid and its esters, sorbic acid etc.；Amidine class, chlorhexidine acetate etc..
Ideal bacteriostatic agent should have the characteristics that：Bacteriostatic activity with wide spectrum has effective in a certain range
Bacteriostatic activity；It works rapid；Itself stable in physicochemical property can keep bacteriostasis for a long time；With the other components and packet in preparation
Package material has good compatibility；The pharmacological toxicology property of drug is not influenced；Do not influence product quality；Using in concentration range
It is safe and non-toxic, it is nonirritant.
Ideal situation is to can reach the above effect using a kind of bacteriostatic agent, not only reduce cost, and can reduce product
Irritation and genotoxic potential, while also reducing the risk of incompatibility between prescription component.Be difficult to find while meeting at present with
The bacteriostatic agent of upper condition, therefore, in the design of specific preparation prescription, selection can meet the antibacterial of requirements above as much as possible
Agent.
However, bacteriostatic agent has gradually caused the concern of clinician and medicament research and development personnel to ocular surface injury.Many scientific researches
Even if personnel studies have shown that benzene prick chlorine by concentration 0.001% hereinafter, if being commonly used or making for a long time more than 30 min
With can cause corneal epithelial cell dysfunction, destroy the barrier of corneal epithelium.Correct selection, reasonable employment bacteriostatic agent are
Guarantee one of eye-drops preparations safety, stability, the key factor of validity.
In eye-drops preparations, since main ingredient, buffer system are different, different product need to select different bacteriostatic agent and appropriate
Concentration, be allowed to generate good inhibitory effect, and keep effect in entire storage and consumer's use process, while most
Reduce to limits injury of the bacteriostatic agent to eyes.In practical prescription screening, can foundation experimental method and requirement, selection not
Same bacteriostatic agent system.By inhibitory effect measurement experiment, the type and minimum effective concentration of bacteriostatic agent are determined.Bacteriostatic agent research
Product Formulation, production, packaging, study on the stability are extended through until during consumer's use.
Based on above-mentioned discovery, the applicant has attempted a series of researchs such as various formulas, various bacteriostatic agents, this is further
Research completes the present invention.
That is, the present invention relates to following proposals：
（1）A kind of ophthalmic solution sodium eye drops, the weight/volume percent containing each component is as follows in every 1 mL：
Ophthalmic solution sodium（In terms of anhydride） 30%
Chitosan 3%~6%
Boric acid 8%~12%
Borax 2%~4%
Purified water is to 1 mL；
（2）It is such as above-mentioned（1）A kind of ophthalmic solution sodium eye drops, wherein pH is in 7.3~7.8 ranges；
（3）It is such as above-mentioned（1）A kind of ophthalmic solution sodium eye drops, wherein the viscosity at 25 DEG C of the eye drops is 4 mPas
Within the scope of~11 mPas；
（4）It is such as above-mentioned（1）A kind of ophthalmic solution sodium eye drops, wherein the osmotic pressure of the eye drops is 270 mOsmol
kg-1~290 mOsmolkg-1In range；
（5）It is such as above-mentioned（1）A kind of ophthalmic solution sodium eye drops, preparation method includes the following steps：
1., boric acid and borax is dissolved in the purified water of 30 DEG C of recipe quantities 90%, chitosan, which is added, is swollen it naturally；
2., the ophthalmic solution sodium of recipe quantity is added solution obtained above 1. in, stir 30 min, afterwards plus purified water is to complete
Amount stirs 5 min；
3., by solution 2. first with 0.45 μm of filtering with microporous membrane, then with 0.22 μm of filtering with microporous membrane, sterile filling to obtain the final product；
（6）It is such as above-mentioned（1）A kind of ophthalmic solution sodium eye drops is preparing the utilization in dry eye drugs.
The inventors discovered that the ophthalmic solution sodium eye drops of preparation, has the eye drops being specifically formulated as described herein
With excellent pharmacy performance.
The beneficial technical effect of the present invention lies in：
1）Ophthalmic solution sodium eye drops of the invention, makees osmotic pressure regulator using borax, unusually stablizes product, passes through shadow
Sound factorial experiments are ground eye drops with original and are studied, and stability significantly increases, and generate without insoluble foreign matter；
2）Ophthalmic solution sodium eye drops of the invention, eye irritation is not experiments have shown that almost have any irritation, safety, side effect
Small, adverse reaction is low；
3）Ophthalmic solution sodium eye drops of the invention, simple process are suitble to industrialization.
By the invention it is possible to which it is more superior by one than existing ophthalmic solution sodium eye drops to provide a kind of irritation, stability
The ophthalmic solution sodium eye drops of the new formula combination of kind.
Specific embodiment
Illustrate the present invention now with reference to following embodiments.These embodiments are provided just to the purpose of illustration, this hair
It is clear and decided to should not be construed as limited to these embodiments, and should be interpreted that cover and appoint according to the teachings provided herein and obviously
Meaning and all variants.
The preparation of Examples 1 to 5 ophthalmic solution sodium eye drops
Preparation process：
1., boric acid and borax is dissolved in the purified water of 30 DEG C of recipe quantities 90%, chitosan, which is added, is swollen it naturally；
2., the ophthalmic solution sodium of recipe quantity is added solution obtained above 1. in, stir 30 min, afterwards plus purified water is to complete
Amount stirs 5 min；
3., by solution 2. first with 0.45 μm of filtering with microporous membrane, then with 0.22 μm of filtering with microporous membrane, sterile filling to obtain the final product.
6 accelerated test stability contrast research of embodiment
40 DEG C ± 2 DEG C of sample what, RH75% ± 5% are placed 6 months, accelerated test investigates stability, as a result as follows；
The result shows that eye drops provided by the invention, stability is significantly better than original and grinds reference preparation, and inhibitory effect during preservation
Quite, indifference.
The test of 7 eye irritation of embodiment
Reference《Chemical induced irritation, anaphylaxis and hemolytic investigative technique guideline》In pertinent regulations, this experiment adopts
Lagophthalmos irritation test is carried out with single administration method and multiple dosing method.
Single administration method
Take health, eyes normal adult rabbit 36, weight（2.7±0.4）Kg is randomly divided into 6 groups, every group 6.By embodiment
1~5 and original grind reference preparation Diquas®0.1 mL is instilled in left eyelid every time, and right eye instills 0.1 mL physiological saline simultaneously and makees
Control.Respectively by 1 h, 24 h, 48 h, 72 h observation cornea, conjunctiva, iris and secretion situation, acetonideexample group is not
See that lagophthalmos is congested, shed tears, the stimulate the reactions such as photophobia, oedema, secretion increase.Check that cornea, iris become using handheld slit lamp
Change, no abnormality seen.Diquas®Group has 2 lagophthalmos part hyperemia occur and shed tears.
Multiple dosing method
Take health, eyes normal adult rabbit 36, weight（2.7±0.4）Kg is randomly divided into 6 groups, every group 6.By embodiment
1~5 and original grind reference preparation Diquas®Each left eye drips 0.1 mL, and right eye drop physiological saline compares, and qid continuously drips 14
It, 1 h, 24 h, 48 h and 72 h check eye before daily administration and after last time administration, record daily office
Portion's response situation, acetonideexample group right and left eyes are showed no exception.Diquas®Group have 4 lagophthalmos occur part is congested, shed tears and
Secretion increases.
The result shows that eye drops on rabbit of the invention is reacted without specific stimulation.It is significantly better than Diquas®Group.
The present invention has been described with reference to certain embodiments herein.However, since its variant is to those skilled in the art
For will become obvious according to proposed disclosure, therefore, the present invention should not be considered limited to this.It enumerates
All patents, patent application and bibliography be incorporated herein by reference of text.
Claims (6)
1. a kind of ophthalmic solution sodium eye drops, the weight/volume percent containing each component is as follows in every 1 mL：
Ophthalmic solution sodium（In terms of anhydride） 30%
Chitosan 3%~6%
Boric acid 8%~12%
Borax 2%~4%
Purified water is to 1 mL.
2. a kind of ophthalmic solution sodium eye drops described in claim 1, it is characterised in that：The pH of the eye drops is 7.3~7.8
In range.
3. a kind of ophthalmic solution sodium eye drops described in claim 1, it is characterised in that：Viscosity at 25 DEG C of the eye drops is
Within the scope of the mPas of 4 mPas~11.
4. a kind of ophthalmic solution sodium eye drops described in claim 1, it is characterised in that：The osmotic pressure of the eye drops is 270
mOsmol·kg-1~290 mOsmolkg-1In range.
5. a kind of preparation method of ophthalmic solution sodium eye drops described in claim 1, it is characterised in that：Include the following steps：
1., boric acid and borax is dissolved in the purified water of 30 DEG C of recipe quantities 90%, chitosan, which is added, is swollen it naturally；
2., the ophthalmic solution sodium of recipe quantity is added solution obtained above 1. in, stir 30 min, afterwards plus purified water is to complete
Amount stirs 5 min；
3., by solution 2. first with 0.45 μm of filtering with microporous membrane, then with 0.22 μm of filtering with microporous membrane, sterile filling to obtain the final product.
6. a kind of ophthalmic solution sodium eye drops described in claim 1 is preparing the utilization in dry eye drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811118247.8A CN108853016A (en) | 2018-09-26 | 2018-09-26 | A kind of ophthalmic solution sodium eye drops and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811118247.8A CN108853016A (en) | 2018-09-26 | 2018-09-26 | A kind of ophthalmic solution sodium eye drops and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108853016A true CN108853016A (en) | 2018-11-23 |
Family
ID=64324837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811118247.8A Withdrawn CN108853016A (en) | 2018-09-26 | 2018-09-26 | A kind of ophthalmic solution sodium eye drops and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853016A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019168023A1 (en) * | 2018-02-28 | 2019-09-06 | 参天製薬株式会社 | Ophthalmic composition comprising diquafosol and cationic polymer |
| CN113712909A (en) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | Compound diquafosol tetrasodium eye drops and preparation method thereof |
| CN113750042A (en) * | 2020-06-05 | 2021-12-07 | 武汉武药科技有限公司 | Pharmaceutical composition and preparation method thereof |
| CN114246826A (en) * | 2020-09-23 | 2022-03-29 | 上海致根医药科技有限公司 | Preservative-free low-irritation single-dose packaged diquafosol sodium eye drops and preparation method thereof |
| CN114306228A (en) * | 2022-01-21 | 2022-04-12 | 山东诺明康药物研究院有限公司 | Diquafosol sodium eye drops and preparation method thereof |
| NL2032726B1 (en) * | 2021-11-23 | 2023-06-15 | Eye Hospital Wenzhou Medical Univ | Diquafosol sustained-release gel, preparation method and use thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090994A1 (en) * | 2010-12-28 | 2012-07-05 | 参天製薬株式会社 | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate |
| CN104220048A (en) * | 2012-02-23 | 2014-12-17 | 参天股份公司 | Self-preserved oil dispersions comprising boric |
| CN106265720A (en) * | 2015-05-12 | 2017-01-04 | 上海昊海生物科技股份有限公司 | A kind of combined artificial tear and preparation method thereof |
| CN107635565A (en) * | 2015-06-05 | 2018-01-26 | 参天制药株式会社 | The dry eye treatment agent being characterized is used in a manner of being instilled into the eye of the patients with dry eye with soft contact lens |
-
2018
- 2018-09-26 CN CN201811118247.8A patent/CN108853016A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090994A1 (en) * | 2010-12-28 | 2012-07-05 | 参天製薬株式会社 | Ophthalmic solution containing diquafosol, method for producing same, and method for preventing formation of insoluble precipitate |
| CN104220048A (en) * | 2012-02-23 | 2014-12-17 | 参天股份公司 | Self-preserved oil dispersions comprising boric |
| CN106265720A (en) * | 2015-05-12 | 2017-01-04 | 上海昊海生物科技股份有限公司 | A kind of combined artificial tear and preparation method thereof |
| CN107635565A (en) * | 2015-06-05 | 2018-01-26 | 参天制药株式会社 | The dry eye treatment agent being characterized is used in a manner of being instilled into the eye of the patients with dry eye with soft contact lens |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019168023A1 (en) * | 2018-02-28 | 2019-09-06 | 参天製薬株式会社 | Ophthalmic composition comprising diquafosol and cationic polymer |
| CN113712909A (en) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | Compound diquafosol tetrasodium eye drops and preparation method thereof |
| CN113750042A (en) * | 2020-06-05 | 2021-12-07 | 武汉武药科技有限公司 | Pharmaceutical composition and preparation method thereof |
| CN113750042B (en) * | 2020-06-05 | 2023-05-05 | 武汉武药科技有限公司 | Pharmaceutical composition and preparation method thereof |
| CN114246826A (en) * | 2020-09-23 | 2022-03-29 | 上海致根医药科技有限公司 | Preservative-free low-irritation single-dose packaged diquafosol sodium eye drops and preparation method thereof |
| NL2032726B1 (en) * | 2021-11-23 | 2023-06-15 | Eye Hospital Wenzhou Medical Univ | Diquafosol sustained-release gel, preparation method and use thereof |
| CN114306228A (en) * | 2022-01-21 | 2022-04-12 | 山东诺明康药物研究院有限公司 | Diquafosol sodium eye drops and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853016A (en) | A kind of ophthalmic solution sodium eye drops and preparation method thereof | |
| CN101317847B (en) | Medicament composition for eyes or nose, and uses thereof | |
| US9308173B2 (en) | Slow-releasing ophthalmic compositions comprising povidone iodine | |
| CN111991415B (en) | Eye care composition and preparation method and application thereof | |
| CN103384514A (en) | Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions | |
| CN113662915B (en) | Ophthalmic pharmaceutical composition | |
| CN111757742A (en) | Ophthalmic composition containing diquafosol and cationic polymer | |
| WO2021039748A1 (en) | Diquafosol or salt thereof, and aqueous ophthalmic composition containing polyvinylpyrrolidone | |
| CN102125577B (en) | New azithromycin ophthalmic preparation composition and preparation method thereof | |
| CN100586436C (en) | Lotepredenol etabonate gernebcin suspension solution and method for preparing the same | |
| CN113662914A (en) | Eye gel containing voriconazole and preparation method and application thereof | |
| Palmer et al. | Tear film, pharmacology of eye drops, and toxicity | |
| KR101723703B1 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| IL296976A (en) | Antimicobial compositions containing polyquaternium | |
| CN103977011A (en) | Travoprost and timolol-containing ophthalmic gel and preparation method thereof | |
| CN108186639A (en) | A kind of pharmaceutical composition of SS 717 | |
| CN103977008B (en) | Gel for eye containing Dorzolamide and timolol and preparation method thereof | |
| CN105213418A (en) | Preoperative compound eye drops of a kind of ophthalmology and preparation method thereof | |
| CN105982843A (en) | Preparation method of moxifloxacin hydrochloride chitosan eye-use gel | |
| CN115227647B (en) | Sodium cromoglicate eye drops without preservative and preparation method thereof | |
| CN109200016A (en) | A kind of Benzydalysine eye drop and preparation method thereof and purposes | |
| CN101045056A (en) | Eyedrops for treating glaucoma and its preparing method | |
| CN102018656A (en) | Eye gel containing latanoprost used as effective component and preparation method thereof | |
| CN109481434B (en) | Eye drops, preparation method and application thereof | |
| CN115212200B (en) | Puerarin-containing compound preparation for treating diabetic complications and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181123 |
|
| WW01 | Invention patent application withdrawn after publication |